The Glaucoma drugs in development market research report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Glaucoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Glaucoma and features dormant and discontinued products.
GlobalData tracks 196 drugs in development for Glaucoma by 161 companies/universities/institutes. The top development phase for Glaucoma is preclinical with 103 drugs in that stage. The Glaucoma pipeline has 173 drugs in development by companies and 22 by universities/ institutes. Some of the companies in the Glaucoma pipeline products market are: Santen Pharmaceutical, NicOx and TearClear.
The key targets in the Glaucoma pipeline products market include Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, and Beta 2 Adrenergic Receptor.
The key mechanisms of action in the Glaucoma pipeline product include Prostaglandin F2 Alpha Receptor Agonist with 21 drugs in Pre-Registration. The Glaucoma pipeline products include 16 routes of administration with the top ROA being Ophthalmic and 14 key molecule types in the Glaucoma pipeline products market including Small Molecule, and Gene Therapy.
Glaucoma overview
Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include eye pain, nausea and vomiting (accompanying the severe eye pain), sudden onset of visual disturbance (often in low light), blurred vision, and reddening of the eye.
For a complete picture of Glaucoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
